RVTY · November 22, 2026 · Free preview
Revvity discounted cash flow valuation
How much cash can Revvity’s diagnostics and life-sciences portfolio generate after replacing acquired technology?
Revvity recorded $254.6 million of acquired-intangible amortization in nine months. That expense is noncash today, but sustaining growth may require new technology and acquisitions. Revvity financial statements
Read the full valuation
See fair value against the November 20 close, the operating margin that price implies, three operating scenarios and the effect of changing the discount rate or long-run growth.